Entering text into the input field will update the search result below

BioXcel Therapeutics slumps 23% after FDA extended PDUFA date for BXCL501

Red arrow And dollar finance decline graph- Stock image

Baris-Ozer/iStock via Getty Images

  • BioXcel Therapeutics (NASDAQ:BTAI) drops 22.8% premarket in reaction to the announcement that the FDA has extended the PDUFA date for its review of the New Drug Application (NDA) of BXCL501 for the acute treatment of agitation

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.